重组人血管内皮抑素联合常规化疗、体部立体定向放疗治疗局部晚期胰腺癌的临床观察

Clinical Observation of Recombinant Human Endostatin Combined with Conventional Chemotherapy and Body Stereotactic Radiotherapy in the Treatment of Locally Advanced Pancreatic Cancer

目的观察重组人血管内皮抑素联合常规化疗、体部立体定向放疗治疗局部晚期胰腺癌的有效性和安全性。方法 64例不能手术切除的局部晚期胰腺癌患者接受体部立体定向放疗、吉西他滨+顺铂化疗、重组人血管内皮抑素靶向治疗。治疗后评价疗效和毒副反应。结果治疗后3个月全组总有效率为73.4%(47/64),生活质量改善率达到78.1%(50/64)。全组患者出现的Ⅲ～Ⅳ度毒副反应主要是白细胞减少(4.7%)、血小板减少(7.8%)及恶心呕吐(6.2%),主要与化疗有关。未出现治疗相关性死亡。结论重组人血管内皮抑素联合吉西他滨+顺铂化疗、体部立体定向放疗治疗局部晚期胰腺癌患者近期疗效较好,毒副反应可耐受,且能提高患者的生存质量,是治疗局部晚期胰腺癌较好的方法。

Objective To evaluate the effectiveness and safety of recombinant human endostatin combined with conventional chemotherapy and body stereotactic radiotherapy in the treatment of locally advanced pancreatic cancer. Methods The 64 patients with inoperable locally advanced pancreatic cancer were treated with body stereotactic radiotherapy, gemcitabine plus eisplatin chemotherapy and targeted therapy of recombinant human endostatin. The efficacy and toxicities were evaluated. Results In three months after treatment, the total response rate was 73.4% （47/64） , the improvement rate of quality of life was 78.1% （50/64）, the main grade Ⅲor Ⅳ toxicities were neutropenia （4.70/o） ,thrombocytopenia （7.8%） ,nausea and vomitting （6.2%） ,and they were related to the chemotherapy. There was no treatment-related deaths. Conclusion Recombinant human endostatin combined with gemcitabine plus cisplatin ehemotherapy and body stereotactic radiotherapy has the good short-term efficacy in the treat- ment of locally advanced pancreatic cancer, the toxicities can be tolerated, and can improve the quality of life, it is one treatment method for locally advanced pancreatic cancer.